Pharmacological and clinical differences among transmucosal fentanyl formulations for the treatment of breakthrough cancer pain: A review article

Minerva Anestesiologica

Volumn 80, Issue 10, 2014, Pages 1123-1134

  Corli, O ^a   Roberto, A ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Breakthrough pain; Fentanyl; Neoplasms; Pain

Indexed keywords

FENTANYL; PLACEBO; NARCOTIC ANALGESIC AGENT;

ANALGESIA; AREA UNDER THE CURVE; ASTHENIA; BREAKTHROUGH PAIN; CANCER PAIN; CANCER PALLIATIVE THERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONFUSION; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSGEUSIA; DYSPNEA; HUMAN; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; MUCOSAL DRUG ADMINISTRATION; PAIN INTENSITY; PLASMA HALF LIFE; PRURITUS; REVIEW; SIDE EFFECT; SNEEZING; SOMNOLENCE; SYSTEMATIC REVIEW; TASTE DISORDER; TIME TO MAXIMUM PLASMA CONCENTRATION; COMPLICATION; MEDICINAL CHEMISTRY; NEOPLASM; PAIN, INTRACTABLE;

ADMINISTRATION, MUCOSAL; ANALGESICS, OPIOID; CHEMISTRY, PHARMACEUTICAL; FENTANYL; HUMANS; NEOPLASMS; PAIN, INTRACTABLE;

EID: 84930005359     PISSN: 03759393     EISSN: 18271596     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Deandrea S, Corli O, Consonni D, Villani W, Greco MT, Apolone G. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manage 2014;47:57-76.
2. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009;13:331-8.
3. Davies A, Buchanan A, Zeppetella G, Porta-Sales J, Likar R, Weismayr W et al. Breakthrough Cancer Pain: An Observational Study of 1000 European Oncology Patients. J Pain Symptom Manage 2013;46:619-28.
4. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-34.
5. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 2000;20:87-92.
6. Enting RH, Oldenmenger WH, van der Rijt CC, Koper P, Lieverse J, Sillevis SP. Nitrous oxide is not beneficial for breakthrough cancer pain. Palliat Med 2002;16:257-9.
7. Christie JM, Simmonds M, Patt R, Coluzzi P, Busch MA, Nordbrock E et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998;16:3238-45.
8. Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. J Opioid Manag 2010;6:97-108.
9. Burton B, Zeppetella G. Assessing the impact of breakthrough cancer pain. Br J Nurs 2011;20:S14, S16-9.
10. Abernethy AP, Wheeler JL, Fortner BV. A health economic model of breakthrough pain. Am J Manag Care 2008;14:S129-40.
11. Dickman A. Integrated strategies for the successful management of breakthrough cancer pain. Curr Opin Support Palliat Care 2011;5:8-14.
12. Greco MT, Corli O, Montanari M, Deandrea S, Zagonel V, Apolone G. Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group. Clin J Pain 2011;27:9-18.
13. Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587-93.
14. Zeppetella G. Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care 2009;3:1-6.
15. Scott JC, Ponganis KV, Stanski DR. EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. Anesthesiology 1985;62:234-41.
16. Meriggi F, Zaniboni A. Fentanyl for breakthrough cancer pain: where are we? Rev Recent Clin Trials 2013;8:42-7.
17. Smith HS. Considerations in selecting rapid-onset opioids for the management of breakthrough pain. J Pain Res 2013;6:189-200.
18. Vissers D, Stam W, Nolte T, Lenre M, Jansen J. Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin 2010;26:1037-45.
19. Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998;90:611-6.
20. Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA et al. Breakthrough cancer pain: a ran-domized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001;91:123-30.
21. Mercadante S, Radbruch L, Davies A, Poulain P, Sitte T, Perkins P et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin 2009;25:2805-15.
22. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22:805-11.
23. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007;5:327-34.
24. Zeppetella G, Messina J, Xie F, Slatkin NE. Consistent and clinically relevant effects with fentanyl buccal tablet in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain. Pain Pract 2010;10:287-93.
25. Davies A, Sitte T, Elsner F, Reale C, Espinosa J, Brooks D et al. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manage 2011;41:358-66.
26. Fallon M, Reale C, Davies A, Lux AE, Kumar K, Stachowiak A et al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol 2011;9:224-31.
27. Kress HG, Oronska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther 2009;31:1177-91.
28. Portenoy RK, Burton AW, Gabrail N, Taylor D. A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010;151:617-24.
29. Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebocontrolled study. Ann Oncol 2010;21:1308-14.
30. Rauck RL, Tark M, Reyes E, Hayes TG, Bartkowiak AJ, Hassman D et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009;25:2877-85.
31. Taylor D, Galan V, Weinstein SM, Reyes E, Pupo-Araya AR, Rauck R. Fentanyl pectin nasal spray in breakthrough cancer pain. J Support Oncol 2010;8:184-90.
32. Mystakidou K, Katsouda E, Parpa E, Tsiatas ML, Vlahos L. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics. J Opioid Manag 2005;1:36-40.
33. Darwish M, Kirby M, Jiang JG. Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet. Expert Opin Pharmacother 2007;8:2011-6.
34. Grassin-Delyle S, Buenestado A, Naline E, Faisy C, Blouquit-Laye S, Couderc LJ et al. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther 2012;134:366-79.
35. Fisher A, Watling M, Smith A, Knight A. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol Ther 2010;48:138-45.
36. Watts P, Smith A. PecSys: in situ gelling system for optimised nasal drug delivery. Expert Opin Drug Deliv 2009;6:543-52.
37. Darwish M, Kirby M, Robertson P, Jr., Hellriegel E, Jiang JG. Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics. Clin Pharmacokinet 2006;45:843-50.
38. Elsner F, Zeppetella G, Porta-Sales J, Tagarro I. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients. Clin Drug Investig 2011;31:605-18.
39. Lyseng-Williamson KA. Fentanyl pectin nasal spray: in breakthrough pain in opioid-tolerant adults with cancer. CNS Drugs 2011;25:511-22.
40. Christrup LL, Foster D, Popper LD, Troen T, Upton R. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther 2008;30:469-81.
41. Lennernas B, Hedner T, Holmberg M, Bredenberg S, Nys-trom C, Lennernas H. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2005;59:249-53.
42. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain 2000;88:287-94.
43. Shaiova L, Lapin J, Manco LS, Shasha D, Hu K, Harrison L et al. Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis. Support Care Cancer 2004;12:268-73.
44. Finn AL, Hill WC, Tagarro I, Gever LN. Absorption and tolerability of fentanyl buccal soluble film (FBSF) in patients with cancer in the presence of oral mucositis. J Pain Res 2011;4:245-51.
45. Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. Clin Drug Investig 2007;27:605-11.
46. Mantyh P. Bone cancer pain: Causes, consequences, and therapeutic opportunities. Pain 2013.